SLOG Vs MFOLFIRINOX As the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

March 26, 2018

Primary Completion Date

November 30, 2019

Study Completion Date

November 30, 2019

Conditions
Locally Advanced or Metastatic Pancreatic Cancer
Interventions
DRUG

S-1

Intervention is administered to patients in this Arm.

DRUG

Leucovorin(oral )

Intervention is administered to patients in this Arm.

DRUG

Gemcitabine

Intervention is administered to patients in this Arm.

DRUG

Oxaliplatin

Intervention is administered to patients in this Arm.

DRUG

Irinotecan

Intervention is administered to patients in this Arm.

DRUG

5-FU

Intervention is administered to patients in this Arm.

DRUG

Leucovorin(IV)

Intervention is administered to patients in this Arm.

Trial Locations (1)

Unknown

National Institute of Cancer Research, Miaoli

All Listed Sponsors
collaborator

National Taiwan University Hospital

OTHER

collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

collaborator

China Medical University Hospital

OTHER

collaborator

National Cheng-Kung University Hospital

OTHER

collaborator

Kaohsiung Medical University

OTHER

collaborator

Taipei Medical University Shuang Ho Hospital

OTHER

collaborator

Chang Gung Memorial Hospital

OTHER

collaborator

Tri-Service General Hospital

OTHER

collaborator

E-DA Hospital

OTHER

lead

National Health Research Institutes, Taiwan

OTHER

NCT03443492 - SLOG Vs MFOLFIRINOX As the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter